Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest McDonald criteria Stories

2012-11-08 08:34:52

GAITHERSBURG, Md., Nov. 8, 2012 /PRNewswire/ -- DioGenix, Inc., a company developing molecular diagnostics for the early diagnosis and monitoring of immune-mediated neurological diseases, today announced its lead product MSPrecise(TM) outperformed the specificity of the current standard of care for cerebral spinal fluid (CSF) analysis in patients suspected of having multiple sclerosis (MS) by almost two to one with no loss of sensitivity. MSPrecise is a proprietary...

2011-12-08 10:03:00

National MS Society Live Webcast December 13 Will Offer MS News You Can Use From Internationally Renowned Researchers NEW YORK, Dec. 8, 2011 /PRNewswire-USNewswire/ -- This year saw exciting research progress in efforts to stop multiple sclerosis, restore function that's been lost and end the disease entirely. At least three emerging therapies are advancing through the pipeline toward FDA review while at least four clinical trials focusing on progressive MS continue to move...

2011-03-09 18:26:16

Use of new data should speed diagnosis -- publication coincides with MS Awareness Week International Panel Revises "McDonald Criteria" for Diagnosing MS -- Use of new data should speed diagnosis -- Publication coincides with MS Awareness Week An international panel has revised and simplified the "McDonald Criteria" commonly used to diagnose multiple sclerosis, incorporating new data that should speed the diagnosis without compromising accuracy. The International Panel on Diagnosis of MS,...

2009-07-29 15:22:05

Cognitive testing may help people with inactive or benign multiple sclerosis (MS) better predict their future with the disease, according to a study published in the July 29, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology. Gender and brain lesions may also determine the risk of progression of MS years after diagnosis.By current definition, people with benign MS are those who remain "fully functional" after 15 or more years from...

2008-09-24 12:00:37

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has announced that the ongoing Improve study met its primary endpoint. The primary objective of the Improve study was to evaluate the efficacy of the new formulation of Rebif, compared to placebo, in patients with relapsing-remitting multiple sclerosis (RRMS) and active disease by means of magnetic resonance imaging (MRI) at the end of 16 weeks of treatment. The 16-week study results show that the mean number of combined unique...

2008-09-17 09:01:00

Merck KGaA has announced that its Merck Serono division has completed patient enrollment in the Reflex trial of Rebif in patients at risk of developing multiple sclerosis. The randomized, double-blind, placebo-controlled, international Phase III trial is designed to evaluate the therapeutic benefit of Rebif (interferon beta-1a) on the time to conversion to multiple sclerosis (MS) in people with a first clinical event suggestive of the disease. A total of 517 patients considered at risk of...